Canada markets closed

Swedish Orphan Biovitrum AB (B6E.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
18.93-0.12 (-0.63%)
At close: 03:44PM CET
Full screen
Loading interactive chart...
  • Reuters

    UPDATE 2-U.S. authorizes Sobi's drug to treat COVID-19 in high-risk patients

    Sobi North America, a unit of Swedish Orphan Biovitrum AB, said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug for treatment of high-risk hospitalized COVID-19 patients. The drug, already approved in the European Union for treating COVID, has been authorized in the United States to treat patients with pneumonia who require oxygen support and those at risk of developing severe respiratory failure. The authorization of Sobi's Kineret adds another option for COVID treatment in the United States, as the disease moves from a pandemic to an endemic stage.

  • GlobeNewswire

    U.S. Food and Drug Administration Issues Emergency Use Authorization for KINERET® (anakinra) for the Treatment of COVID-19-Related Pneumonia

    Early treatment with KINERET reduced disease progression by 64 percent in hospitalized COVID-19 patientsi WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for KINERET® (anakinra) for the treatment of Coronavirus Disease 2019 (COVID-19) in adult patients who are hospitalized with positive results of d

  • Zacks

    Swedish Orphan Biovitrum (BIOVF) Beats Q3 Earnings Estimates

    Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 16.67% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?